PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLevocarnitine
Levocarnitine
Carnitor, Levocarnitine (levocarnitine) is a small molecule pharmaceutical. Levocarnitine was first approved as Carnitor on 1985-12-27. It is used to treat deficiency diseases in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Carnitor, Carnitor sf, Levocarnitine, Levocarnitine sf (discontinued: Carnitor, Levocarnitine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levocarnitine
Tradename
Company
Number
Date
Products
CARNITORLeadiant BiosciencesN-018948 RX1985-12-27
1 products, RLD, RS
CARNITORLeadiant BiosciencesN-020182 RX1992-12-16
1 products, RLD, RS
CARNITORLeadiant BiosciencesN-019257 RX1986-04-10
1 products, RLD, RS
CARNITOR SFLeadiant BiosciencesN-019257 RX2007-03-28
1 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
carnitorNew Drug Application2024-10-30
carnitor sfNew Drug Application2024-11-04
levocarnitineANDA2025-07-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
deficiency diseasesEFO_1001067D003677E63
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
A16: Other alimentary tract and metabolism products in atc
A16A: Other alimentary tract and metabolism products in atc
A16AA: Amino acids and derivatives
A16AA01: Levocarnitine
HCPCS
Code
Description
J1955
Injection, levocarnitine, per 1 gm
Clinical
Clinical Trials
292 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20821516
FatigueD005221R53.83461515
SyndromeD013577631513
Chronic kidney failureD007676EFO_0003884N18.6821111
Male infertilityD007248EFO_0004248N4612169
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8121249
Peripheral nervous system diseasesD010523G6443119
Fatty liverD005234EFO_000393421238
MalnutritionD044342EFO_0008572E40-E461438
Peripheral arterial diseaseD058729EFO_00042652226
Show 44 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I5025217
Type 2 diabetes mellitusD003924EFO_0001360E113115
Muscular atrophyD00913313115
Diabetes mellitusD003920EFO_0000400E08-E132114
DyslipidemiasD0501712114
Septic shockD012772A48.32214
Spinal muscular atrophyD009134EFO_0003823G12.11314
AtrophyD0012841314
Covid-19D000086382U07.12113
SpasmD013035M62.83123
Show 62 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients257
Diet therapyD004035134
Cardiovascular diseasesD002318EFO_0000319I98123
Mitochondrial diseasesD028361EFO_0000591123
OligospermiaD009845N46.1112
LeukemiaD007938C95112
EpilepsyD004827EFO_0000474G40.9112
Drug resistant epilepsyD000069279112
Chronic progressive multiple sclerosisD020528EFO_000384011
PancreatitisD010195EFO_0000278K8511
Show 15 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Brain diseasesD001927G93.4044
Glucose intoleranceD018149HP_0000833R73.0333
ObesityD009765EFO_0001073E66.933
HyperlipidemiasD006949EFO_0003774E78.533
Weight lossD01543133
Hepatic encephalopathyD006501K72.9133
Liver cirrhosisD008103EFO_0001422K74.022
OverweightD050177E66.322
HumansD006801STY/T01622
Culture mediaD00347022
Show 79 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLevocarnitine
INNlevocarnitine
Description
Carnitine is an amino-acid betaine that is butanoate substituted with a hydroxy group at position C-3 and a trimethylammonium group at C-4. It has a role as a human metabolite and a mouse metabolite. It is functionally related to a butyrate. It is a conjugate base of a carnitinium.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[N+](C)(C)C[C@H](O)CC(=O)[O-]
Identifiers
PDB
CAS-ID541-15-1
RxCUI
ChEMBL IDCHEMBL1149
ChEBI ID16347
PubChem CID288
DrugBankDB00583
UNII ID0G389FZZ9M (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Levocarnitine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 63,709 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
630 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use